Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

European Innovation Council · Running

ISOS ISOS-Implantable Ecosystems of Genetically Modified Bacteria for the Personalized Treatment of Patients with Chronic Diseases

Coordinator
Silk Biomed, S.l., Spain
Runs
1 December 2023 to 30 November 2026
Status
Running
EU funding
€2.4m
Total cost
€2.4m
Partners
7 organisations in 4 countries
Type
European Innovation Council
Grant agreement
101130454

What the project is doing

In the project's own words, from its summary on CORDIS.

In ISOS we propose to develop the first biomedical product for the in-situ fabrication and auto-renewed delivery of therapeutic compounds employing complex ecosystems of probiotic genetically engineered bacteria (GEB) integrated in a biomaterial-based bioreactor. ISOS is designed to treat chronic diseases requiring lengthy treatments. The encapsulated GEB populations produce the therapeutic molecules ""on demand"", stimulated by the signals of the pathological environment within the patient, i.e., inflammation and/or reactive oxygen species.

Bacteria populations interact among them to maintain a dynamic equilibrium of the GEB species and to guarantee the survival of the drug-producing GEB as long as the disease persists. The GEB ecosystem is designed in such a way that bacteria cannot survive outside of the encapsulating biomaterial, to meet future biosafety and regulatory requirements. The design and the configuration of the GEB ecosystem will be personalized for each patient, and it will be done using in-silico tools and synthetic biology.

As a Proof-of-Concept, we propose to engineer an implantable GEB-based bioreactor for the therapy of the wet form of age-related macular degeneration (wAMD), which is caused by an abnormal production of Vascular Endothelial Growth factor (VEGF). This Proof-of-Concept will demonstrate the ability of ISOS to replace the repeated intraocular injections of Anti-VEGF molecules (current treatment) with a single ISOS bioreactor that will enhance the therapeutic response and minimize side effects due the molecular crosstalk between ISOS and the pathological environment.

ISOS will establish the principles of a new generation of therapeutic products that will use recombinant probiotic bacteria strains libraries for personalized treatments with rigorous control of local drug production and efficient delivery based of dynamic variation of pathological signals.""

Topics

Who is involved

OrganisationCityCountryRole
Silk Biomed, S.l.GalapagarSpainCoordinator
Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eVMunchenGermanyParticipant
Universitaet LeipzigLeipzigGermanyParticipant
Indeep Artificial Intelligence SLLas Palmas De Gran CanariaSpainThird party
Universidad Complutense De MadridMadridSpainParticipant
Alien Tt Italy S.r.l.RomaItalyParticipant
University of Northumbria at NewcastleNewcastle Upon TyneUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI